Study shows positive efficacy of Bimuno
READING, England New data published Friday in the American Journal of Clinical Nutrition found that the prebiotic supplement brand Bimuno significantly increases levels of bifidobacteria in humans within seven days.
According to Clasado, which markets Bimuno, bifidobacteria are the most important types of positive bacteria in the gut, as they specifically stimulate the immune system, increase resistance to infection and diarrheal disease, reduce markers of chronic gut problems and enhance overall gut health.
“When considering increasing your good bacteria with a supplement, it is important to target the right bacteria as some bacteria have wider health benefits than others,” stated Liz Tucker, health and wellbeing consultant. “Today’s new data shows that unlike many prebiotics or indeed probiotics, Bimuno is non-digestible, gets to where it is needed in the gut—intact—and is designed to specifically target the best of the good bacteria, bifidobacteria.”
Abkit rolls out new flavors of Zucol Coldcare
DESTIN, Fla. Abkit, which launched its two Zucol Coldcare exclusively in Rite Aid earlier this year, showcased its menthol- and orange creme-flavored homeopathic SKUs to buyers at the ECRM Cough & Cold and Allergy here this past week. The same formula marketed by parent company Schwabe is the No. 1 OTC brand in Germany, under the Umckaloabo brand name, where it generates $230.7 million in annual sales, Abkit executives reported.
The homeopathic ingredients in Zucol are supported by some 19 clinical trials which included results from almost 3,000 patients.
Zyrtec-D added to Perrigo’s private label
ALLEGAN, Mich. Perrigo on Thursday added Zyrtec-D to its private label offerings, following final Food and Drug Administration approval of Teva Pharmaceutical’s abbreviated new drug application for an over-the-counter version of cetirizine hydrochloride, pseudoephedrine hydrochloride extended-release tablets, 5 mg/120 mg.
According to Wolters Kluwer data, brand sales for the original prescription strength version of the product for the 12 months ending December 2007 were approximately $190 million.
“This approval and marketing agreement reflect our strategy to be first to market with the important products that make quality healthcare more affordable for our customers and drive value for our shareholders,” stated Perrigo’s chairman and chief executive officer Joseph Papa.
Perrigo expects to begin shipping the product in the next 90 days.